TG Therapeutics IncNASDAQ:TGTX
- LAST PRICE24.4300
- TODAY'S CHANGE (%)0.0700 (0.2874%)
- Bid / Lots24.4200/ 10
- Ask / Lots24.4400/ 3
- Open / Previous Close24.4900 / 24.3600
- Day Range
- 52 Week Range
- Volume1,146,033
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TGTX |
|---|---|---|
| 09:32 ET | 42292 | 24.6 |
| 09:33 ET | 18506 | 24.35 |
| 09:35 ET | 21599 | 24.1366 |
| 09:37 ET | 40114 | 24.07 |
| 09:39 ET | 18225 | 23.8549 |
| 09:42 ET | 24156 | 24.025 |
| 09:44 ET | 9235 | 23.925 |
| 09:46 ET | 32618 | 23.95 |
| 09:48 ET | 11400 | 23.92 |
| 09:50 ET | 12142 | 24.043 |
| 09:51 ET | 11132 | 23.9529 |
| 09:53 ET | 6081 | 23.9 |
| 09:55 ET | 23705 | 23.85 |
| 09:57 ET | 22142 | 23.7 |
| 10:00 ET | 21764 | 23.706678 |
| 10:02 ET | 12762 | 23.635 |
| 10:04 ET | 13690 | 23.78 |
| 10:06 ET | 16817 | 23.9 |
| 10:08 ET | 25234 | 23.91 |
| 10:09 ET | 15117 | 24.14 |
| 10:11 ET | 22675 | 24.22 |
| 10:13 ET | 27902 | 24.31 |
| 10:15 ET | 6793 | 24.22 |
| 10:18 ET | 9764 | 24.16 |
| 10:20 ET | 6240 | 24.2 |
| 10:22 ET | 5685 | 24.22 |
| 10:24 ET | 6929 | 24.105 |
| 10:26 ET | 4350 | 24.1 |
| 10:27 ET | 8336 | 24.23 |
| 10:29 ET | 2971 | 24.16 |
| 10:31 ET | 3350 | 24.09 |
| 10:33 ET | 4216 | 24.16 |
| 10:36 ET | 4968 | 24.095 |
| 10:38 ET | 4414 | 24.035 |
| 10:40 ET | 4270 | 23.99 |
| 10:42 ET | 9230 | 24.065 |
| 10:44 ET | 3775 | 24.17 |
| 10:45 ET | 9907 | 24.22 |
| 10:47 ET | 24300 | 24.16 |
| 10:49 ET | 3304 | 24.03 |
| 10:51 ET | 2960 | 24.12 |
| 10:54 ET | 3600 | 24.13 |
| 10:56 ET | 11016 | 24.19 |
| 10:58 ET | 3879 | 24.2151 |
| 11:00 ET | 22823 | 24.335 |
| 11:02 ET | 10459 | 24.26 |
| 11:03 ET | 2070 | 24.255 |
| 11:05 ET | 6055 | 24.32 |
| 11:07 ET | 6693 | 24.36 |
| 11:09 ET | 9600 | 24.28 |
| 11:12 ET | 2756 | 24.23 |
| 11:14 ET | 6373 | 24.1867 |
| 11:16 ET | 2377 | 24.3 |
| 11:18 ET | 9214 | 24.295 |
| 11:20 ET | 6268 | 24.285 |
| 11:21 ET | 4084 | 24.33 |
| 11:23 ET | 29050 | 24.37 |
| 11:25 ET | 4201 | 24.44 |
| 11:27 ET | 7773 | 24.36 |
| 11:30 ET | 23911 | 24.385 |
| 11:32 ET | 14950 | 24.31 |
| 11:34 ET | 2922 | 24.32 |
| 11:36 ET | 3316 | 24.33 |
| 11:38 ET | 6968 | 24.385 |
| 11:39 ET | 2250 | 24.375 |
| 11:41 ET | 5241 | 24.3986 |
| 11:43 ET | 7687 | 24.385 |
| 11:45 ET | 6168 | 24.39 |
| 11:48 ET | 3050 | 24.385 |
| 11:50 ET | 5314 | 24.435 |
| 11:52 ET | 7935 | 24.5 |
| 11:54 ET | 28468 | 24.49 |
| 11:56 ET | 6825 | 24.5 |
| 11:57 ET | 17441 | 24.45 |
| 11:59 ET | 8318 | 24.365 |
| 12:01 ET | 17311 | 24.265 |
| 12:03 ET | 5519 | 24.29 |
| 12:06 ET | 3922 | 24.315 |
| 12:08 ET | 1008 | 24.345 |
| 12:10 ET | 3987 | 24.415 |
| 12:12 ET | 6571 | 24.38 |
| 12:14 ET | 2756 | 24.4207 |
| 12:15 ET | 6188 | 24.43 |
| 12:17 ET | 1471 | 24.43 |
Yesterday
*DJ TG Therapeutics 3Q EPS 2c >TGTX, from 7:00AM ET on Monday Nov 04, 2024 by Dow Jones
7:00AM ET on Monday Nov 04, 2024 by Dow JonesTG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI(R) (ublituximab-xiiy) Full Year Revenue Guidance, from 7:00AM ET on Monday Nov 04, 2024 by Dow Jones
7:00AM ET on Monday Nov 04, 2024 by Dow Jones
Nov 1, 2024
TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update, from 8:06AM ET on Friday Nov 01, 2024 by Dow Jones
8:06AM ET on Friday Nov 01, 2024 by Dow Jones
Oct 29, 2024
DJ TG Therapeutics Initiated at Buy by TD Cowen, from 6:03AM ET on Tuesday Oct 29, 2024 by Dow Jones
6:03AM ET on Tuesday Oct 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TG Therapeutics Inc | 3.8B | -229.0x | --- |
Axsome Therapeutics Inc | 4.2B | -13.5x | --- |
Denali Therapeutics Inc | 3.9B | -9.5x | --- |
ADMA Biologics Inc | 4.5B | 133.3x | --- |
Zai Lab Ltd | 3.1B | -10.1x | --- |
Alvotech SA | 3.9B | -4.9x | --- |
Company Information
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Contact Information
- Headquarters
- 3020 Carrington Mill Blvd., Suite 475MORRISVILLE, NC, United States 27560-5435
- Phone
- 212-554-4484
- Fax
- 212-554-4531
Executives
- Chairman of the Board, President, Chief Executive Officer
- Michael Weiss
- Chief Financial Officer, Treasurer, Corporate Secretary
- Sean Power
- Lead Independent Director
- Laurence Charney
- Independent Director
- Yann Echelard
- Independent Director
- Kenneth Hoberman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.8B |
|---|---|
Revenue (TTM) | $264.8M |
Shares Outstanding | 154.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.18 |
EPS | $-0.11 |
Book Value | $1.06 |
P/E Ratio | -229.0x |
Price/Sales (TTM) | 14.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -0.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
